UCAM HiTech, Sport & Health Innovation Hub
Murcia, Spain
Location status: Recruiting
NCT Number: NCT07420998
Randomized, controlled, double-blind clinical trial with two parallel arms based on the product consumed (experimental product and placebo product) and conducted at a single center, to measure the efficacy of the liquid NUTIFOOD product (nutritional product with carob extract) on carbohydrate metabolism.
Interested in participating?
Request Info18 year–65 year
All sexes
Interventional
Not applicable
Murcia, Spain
Location status: Recruiting
This study evaluates the effects of NUTIFOOD (liquid nutritional product with carob extract) on insulin sensitivity and carbohydrate metabolism in subjects with abnormal glucose or HbA1c levels not on antidiabetic medication, over 90 days.
Key assessments include: Glucose response (AUC and peak levels) during an oral glucose tolerance test. Changes in fasting glucose, HbA1c, and basal insulin. Insulin resistance measured by HOMA-IR and QUICKI. Effects on body composition. Safety and tolerability of the product.
The study aims to determine the potential of NUTIFOOD as a nutritional intervention to improve glucose regulation and metabolic health.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will consume two doses per day. The product should be taken 30 minutes before the two main meals of the day.
Other names: Carob liquid - GippsNature
Participants will consume two daily doses of the placebo product. The product should be taken 30 minutes before the two main meals of the day.
Other names: Placebo
Time frame: Measurements will be performed at baseline, Day 45, and Day 90
Fasting glycated hemoglobin (HbA1c) will be measured in venous blood samples to assess long-term glycemic control.
Time frame: This assessment will be conducted at baseline, Day 45, and Day 90.
The area under the curve (AUC) of blood glucose will be calculated during an oral glucose tolerance test (OGTT) using a 50-g glucose load. Capillary blood glucose levels will be measured at 0, 15, 30, 45, 60, 90, and 120 minutes after glucose ingestion.
Time frame: These measurements will be performed at baseline, Day 45, and Day 90.
Fasting venous insulin levels will be measured at baseline. Post-load venous insulin concentrations will be determined at 45 and 90 minutes during the oral glucose tolerance test (50-g glucose load).
Time frame: They will be calculated at the start of the study, on day 45, and on day 90.
Peripheral insulin resistance will be assessed using validated surrogate indices derived from fasting glucose and insulin levels: HOMA-IR (Homeostatic Model Assessment of Insulin Resistance)
Time frame: It will be calculated at the start of the study, on day 45, and on day 90.
Insulin sensitivity will be assessed using validated surrogate indices derived from fasting glucose and insulin levels: QUICKI (Quantitative Insulin Sensitivity Check Index).
Time frame: These measurements will be performed at baseline, Day 45, and Day 90.
Body composition will be assessed using bioelectrical impedance analysis (BIA), providing estimates of fat mass, lean mass, and total body water.
Time frame: These measurements will be performed at baseline, on day 45, and on day 90.
It is a blood test that measures the presence of some enzymes, proteins and bilirubin in the blood, with the aim of determining if there is any alteration in the liver. Enzyme GPT, GOT, Gamma GT, LDH, alkaline phosphatase and bilirubin (UI/L)
Time frame: At 12 weeks after consumption
It will be evaluated at each of the visits.
Contact information is provided by the study sponsor or research team.
Universidad Católica San Antonio de Murcia
Other
Randomized Clinical Trial on the Effect of a Nutritional Product Containing Carob Extract (NUTIFOOD) on Carbohydrate Metabolism in Glucose-intolerant Subjects
Acronym: NUTIFOOD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06007404
Body Weight, Diabetes Mellitus
Ann Arbor, Michigan, United States
View Trial DetailsNCT07546409
Brain Diseases, Central Nervous System Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT07624500
Diabetes Mellitus, Endocrine System Diseases
Chicago, Illinois, United States
View Trial DetailsNCT07131384
Behavior, Diabetes Mellitus
Charlottesville, Virginia, United States
View Trial Details